Diebold Nixdorf Authorizes $250 Million Share Buyback as Previous Program Nears Completion
Key Facts
Diebold Nixdorf’s board authorized a new program on October 28 to repurchase up to $250 million of common stock, according to a company statement published via PR Newswire. The decision comes as the previous $200 million program nears completion; the company announced it on November 5, 2025. Chief Financial Officer Tom Timko said the new program gives the company “additional flexibility to return capital while continuing to invest in strategic opportunities across our businesses.” The authorization sets a ceiling on potential purchases, but does not mean the company will spend the full amount or make immediate purchases. The announcement coincided with the investor call to discuss third-quarter results, making capital allocation a parallel focus alongside the company’s operating performance.
Company filings with the Securities and Exchange Commission show that a substantial portion of the previous program had been used before the new authorization was announced. In the first half of 2026, Diebold Nixdorf repurchased 1,498,258 shares for $115 million under that program. Those purchases represent more than half of the previous program’s $200 million ceiling, while the October 28 statement described the program as “nearing completion.” The new authorization does not specify a target number of shares, with its maximum value set in dollars. Moving to a new program gives the company the ability to continue repurchases after the previous program ends, while leaving actual purchases dependent on execution conditions.
According to the statement, purchases may be made in the open market, including through one or more accelerated share repurchase plans, or under plans that comply with Rule 10b5-1. The company said the timing, price and volume of purchases will depend on prevailing share prices, market and economic conditions, and other factors. The statement also said the authorization “does not obligate us to purchase any specific number of shares of common stock,” and that the company may suspend or terminate the program. The announcement therefore sets no timetable for purchases and does not guarantee that spending will reach the authorized maximum. It reflects a range of execution options, while the company retains the flexibility to adjust the pace of repurchases in response to the conditions cited in the statement.
The buyback decision follows second-quarter results that showed year-over-year GAAP revenue growth of more than 1%, a 3% increase in order intake and a 28% rise in net income, according to the results statement filed with the Securities and Exchange Commission. On July 29, the company reaffirmed its fiscal 2026 outlook, setting a revenue range of $3.86 billion to $3.94 billion and an adjusted EBITDA range of $510 million to $535 million. These figures provide operating context for the capital allocation announcement, as Timko’s comment linked returning capital with continuing to invest in opportunities across the company’s businesses. The statement does not tie the new program to any specific second-quarter result or to a change in the annual outlook.
The company’s statement describes it as having a presence in more than 100 countries and employing about 20,000 people worldwide. In the stock market, DBD shares closed at $66.68 on October 27, according to EL7 data; the available data do not include the session high or low. The announcement did not report a figure for purchases executed under the new program to date or a price impact from the decision. The next scheduled event listed by the company was its third-quarter earnings call on October 28, 2026, to discuss results with investors.